CBG properties and effects: how it differs from CBD and who it is better for

CBG, or cannabigerol, is sometimes called the mother of all cannabinoids because its acidic form gives rise to other compounds in the cannabis plant. For years, it was a trace component in cannabis products until breeders developed strains that retain it in larger amounts. For several years now, it has been sold as a separate supplement, and product descriptions attribute stimulating effects and support for focus during the day, in contrast to the supposedly calming CBD. Available scientific works say otherwise, and in the case of the mechanism itself, directly the opposite. This article compares what is really known about cannabigerol from research with what can be read on the label and shows where the line between the two lies.

KEY INFORMATION
• CBG is a biochemical precursor of the most numerous cannabinoids of the cannabis plant (Nachnani, Raup-Konsavage, Vrana, Journal of Pharmacology and Experimental Therapeutics, 2021).
• In pharmacological studies, CBG proved to be a strong agonist of alpha-2 adrenergic receptors, not their blocker (Cascio et al., British Journal of Pharmacology, 2010). This reverses the popular explanation of stimulating action.
• In a survey of 127 people using CBG-dominant products, the most frequently indicated reasons were anxiety (51.2%), chronic pain (40.9%), depression (33.1%), and insomnia (30.7%). Concentration was not on this list (Russo et al., Cannabis and Cannabinoid Research, 2022).
• The strongest data concern animal models and cell cultures: colitis, Huntington’s disease, colorectal cancer, and MRSA infections.
• There are practically no studies on CBG involving humans, and the available pharmacological review directly warns of the gap between sales promises and the state of knowledge.

What is CBG and where does it come from in the cannabis plant?

CBG is a plant cannabinoid whose acidic form, CBGA, is the starting compound for other cannabinoids in cannabis. The plant’s enzymes convert CBGA into acids, which after decarboxylation become CBD, THC, and CBC. Therefore, in a mature plant, little cannabigerol remains: the more efficiently the conversion works, the less starting material remains unchanged.

A pharmacological review published in Journal of Pharmacology and Experimental Therapeutics describes CBG as a parent molecule for the most numerous phytocannabinoids and at the same time as a compound studied incomparably less than CBD. The authors point out that CBG reached the market as a dietary supplement before studies could confirm its attributed effects. This gap is directly stated in their text and is worth keeping in mind when reading product descriptions.

The breeding consistency is simple. Since CBGA is consumed for other cannabinoids, high CBG content is provided by strains with limited conversion or harvesting done earlier, before the transformation can take place. Hence a separate category of strains described as high-CBG, from which isolates and extracts with a predominance of cannabigerol are produced. The mechanism of cannabinoid formation from a single precursor is discussed more broadly in the entry about THCA and its differences from THC, and the third branch of the same pathway is treated in the text about cannabichromene.

How does CBG work and how does it differ from CBD?

CBG has a different molecular target profile than CBD, and this is a real difference between these compounds. It was most fully described by the Cascio team’s study, published in British Journal of Pharmacology. The authors checked whether cannabigerol stimulates or blocks G protein-coupled receptors and obtained a picture that deviates from what is repeated in sales texts.

In mouse brain membranes, CBG behaved as a strong agonist of the alpha-2 adrenergic receptor, with a half-maximal effect concentration of 0.2 nanomoles. Against the serotonin receptor 5-HT1A, it acted in the opposite way, as an antagonist. At a concentration of 10 micromoles, it proved to be a competitive antagonist of the CB1 receptor, showing significant affinity for both CB1 and CB2. Another study added to this the blocking of the TRPM8 channel and inhibition of endocannabinoid reuptake.

Thus, the comparison with CBD turns out differently than the popular division into calming and stimulating cannabinoids suggests. A 2021 review summarizes CBG’s position as intermediate between THC and CBD on cannabinoid receptors, and its distinguishing feature is its interaction with alpha-2 and 5-HT1A.

Does CBG really support concentration?

There is no study that has shown this, and the most commonly repeated explanation of the mechanism is reversed. Advertising texts explain the alleged stimulating effect by stating that CBG blocks alpha-2 receptors and thus increases norepinephrine release. The Cascio team’s work shows the opposite: cannabigerol stimulates these receptors. Drugs that work in the same way, such as clonidine or guanfacine, lower sympathetic tone and can be sedative.

The second argument comes from a survey published in Cannabis and Cannabinoid Research. It included 127 people from the USA who used products containing over 50% CBG for six months. When asked about their reasons for using them, they indicated anxiety (51.2%), chronic pain (40.9%), depression (33.1%), and insomnia and sleep disorders (30.7%). Concentration or focus did not appear on this list at all. Among the side effects, 15% of respondents reported drowsiness, which also does not fit the picture of a stimulating agent.

This same survey shows why user opinions can be easily overinterpreted. Effectiveness was rated very highly, with 73% to 80% of respondents considering CBG-dominant products better than the medications previously used for their condition. However, these are declarations collected online, without a control group and without measuring anything. The authors conclude that CBG requires randomized studies, not that it replaces them.

What have studies on CBG shown in neurodegenerative diseases?

The best-documented direction is Huntington’s disease, and these are studies on mice. The Valdeolivas team described in Neurotherapeutics two models at once. In animals poisoned with 3-nitropropionic acid, cannabigerol proved to be clearly neuroprotective: it improved motor deficits, protected striatal neurons, suppressed reactive microgliosis, and raised the lowered level of antioxidant defense.

In the genetic model R6/2, the effect was much weaker, though still statistically significant: improvement concerned maintenance on a rotating cylinder. Gene expression analysis showed that some of the genes disturbed in these mice returned closer to normal after CBG, and the aggregation of mutated huntingtin in the striatum decreased slightly but significantly. The authors cautiously formulate the conclusion as opening a direction for research, not as a ready therapy.

A 2021 review also mentions Parkinson’s disease and multiple sclerosis as areas where CBG may have therapeutic potential. However, there is a difference from what is sometimes written about cannabigerol on the internet: the attributed effects in amyotrophic lateral sclerosis are not confirmed by any work that could be found in medical databases. All results described in this section come from animals.

Does CBG have antibacterial effects?

Yes, and this is an area where cannabigerol is most interesting. The Farha team published in ACS Infectious Diseases a study showing that cannabinoids inhibit methicillin-resistant Staphylococcus aureus, or MRSA. The effect does not end with growth inhibition: the studied compounds blocked biofilm formation and also destroyed already formed biofilm and cells in the stationary phase, which usually survive antibiotic therapy.

The mechanism was established separately for CBG. Cannabigerol attacks the cytoplasmic membrane of Gram-positive bacteria, thus acting physically on the cell structure, rather than through a single enzymatic pathway. Effectiveness was also confirmed in a living organism, in a mouse model of generalized infection caused by MRSA. Against Gram-negative bacteria, whose outer membrane normally serves as a barrier, CBG acted after its disruption, hitting the inner membrane.

The authors also checked combinations with antibiotics. Cannabinoids given together with polymyxin B fought multidrug-resistant Gram-negative pathogens, opening a direction for combination therapy. However, it should be noted, which marketing omits: this is a laboratory and mouse study, not a clinical study. None of these observations translate to the use of CBG in human infection and do not replace antibiotics.

What is known about CBG, the intestines, and cancer cells?

Two works by the Borrelli team from Naples concern the colon and both were performed on animal models and cell cultures. The first, published in Biochemical Pharmacology, studied colitis induced in mice by dinitrobenzenesulfonic acid. Cannabigerol reduced the ratio of mass to length of the colon, myeloperoxidase activity, and expression of inducible nitric oxide synthase, increased superoxide dismutase activity, and normalized disturbed levels of interleukin 1-beta, interleukin 10, and gamma interferon.

The second work, from Carcinogenesis, examined anticancer effects. In colorectal cancer cells, CBG triggered apoptosis, increased the production of reactive oxygen species, and limited cell growth. The effect depended on blocking the TRPM8 channel: in cells with silenced TRPM8, it was weaker, and other blockers of this channel mimicked it. In a living organism, cannabigerol inhibited the growth of tumors transplanted into mice and the development of chemically induced colon cancer.

None of these results should be read as a basis for using CBG in inflammatory bowel disease or cancer. There are simply no studies involving humans in both indications, and the authors of both works write about a premise for further research. The same problem of discrepancy between laboratory data and clinical practice is discussed more broadly in the entry about cannabis and cancer diseases.

Does CBG lower intraocular pressure and is it safe?

The ophthalmic thread is based on two works by Colasanti from the 1980s and 1990s, both performed on cats. Their most important result is often overlooked: after a single administration of drops, the decrease in intraocular pressure was only slight. A clear effect, in the range of 4-7 mm Hg, appeared only with chronic administration via an osmotic pump (Colasanti, Journal of Ocular Pharmacology, 1990). Neither THC nor CBG changed the rate of aqueous humor production, while both two- to threefold increased its outflow ease.

An earlier work from Experimental Eye Research compared cannabigerol with cannabinol and was favorable for CBG in terms of tolerance. Cannabinol caused conjunctival hyperemia and changes in the electrical activity of the brain in rats, while cannabigerol did not cause either. This is the only safety premise that can be drawn from these studies, and it concerns animals.

Almost nothing is known about the safety of CBG in humans. A 2021 review devotes a separate section to potential toxicological hazards and emphasizes that for an unregulated molecule sold as a supplement, there should be much more data. A survey among 127 users noted that 44% reported no adverse effects, and among those reported: dry mouth (16.5%), drowsiness (15%), increased appetite (11.8%), and dry eyes (8.7%). If you are taking prescription medications, discuss the decision to use a CBG product with your doctor, as there is no data on interactions.

Frequently asked questions

What is CBG and how does it work?

CBG is a plant cannabinoid, a precursor to other cannabinoids in cannabis. In pharmacological studies, it behaved as a strong agonist of alpha-2 adrenergic receptors, an antagonist of the 5-HT1A receptor, and a competitive antagonist of CB1, showing affinity for both CB1 and CB2. It also blocks the TRPM8 channel.

How does CBG differ from CBD?

They differ in molecular targets. A 2021 review places CBG on cannabinoid receptors between THC and CBD, and its distinguishing feature is its interaction with alpha-2 adrenergic and 5-HT1A receptors. CBD is much better studied, especially in humans.

Does CBG stimulate and improve concentration?

There is no study that has shown this. The popular explanation of the mechanism is reversed: CBG stimulates alpha-2 receptors, rather than blocking them. In a survey of 127 users, concentration was not among the reasons for use, and 15% reported drowsiness.

Is CBG psychoactive?

Cannabigerol does not cause intoxication and is not listed in the Polish register of controlled substances, where the name cannabigerol does not appear even once. In pharmacological studies, it acted on the CB1 receptor as an antagonist, which is the opposite of the intoxicating THC.

What have studies on CBG really shown?

The strongest results come from animal models and cell cultures: neuroprotection in Huntington’s disease in mice, alleviation of colitis in mice, inhibition of colorectal cancer development, and activity against MRSA. There are practically no studies involving humans.

Can CBG be combined with CBD?

In full-spectrum products, both compounds naturally occur together, and no dangerous interactions between them have been described. However, there are no studies that define beneficial ratios or confirm the superiority of the combination over a single ingredient. Discuss the decision with your doctor if you are on prescription medications.

Products with cannabigerol available in the store at Bucha can be found in the oils category.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-06-02 · Updated: 2026-08-11